Citigroup’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-775
Closed -$11.6K 6100
2022
Q4
$11.6K Sell
775
-4,145
-84% -$57.4K ﹤0.01% 4793
2022
Q3
$40K Sell
4,920
-400
-8% -$3.07K ﹤0.01% 4494
2022
Q2
$35K Buy
5,320
+3,860
+264% +$18.7K ﹤0.01% 4709
2022
Q1
$8K Buy
+1,460
New +$6.01K ﹤0.01% 5664
2021
Q3
Sell
-24
Closed 6573
2021
Q2
$0 Sell
24
-1,422
-98% -$9.8K ﹤0.01% 6625
2021
Q1
$11K Sell
1,446
-2,666
-65% -$23K ﹤0.01% 5614
2020
Q4
$24K Buy
4,112
+3,044
+285% +$17.4K ﹤0.01% 6547
2020
Q3
$6K Sell
1,068
-718
-40% -$3.55K ﹤0.01% 6965
2020
Q2
$9K Buy
1,786
+1,766
+8,830% +$11.1K ﹤0.01% 7122
2020
Q1
$0 Sell
20
-1,775
-99% -$8.81K ﹤0.01% 7924
2019
Q4
$12K Sell
1,795
-1,240
-41% -$9.13K ﹤0.01% 7162
2019
Q3
$25K Sell
3,035
-1,016
-25% -$7.56K ﹤0.01% 6602
2019
Q2
$27K Buy
4,051
+1,229
+44% +$10.5K ﹤0.01% 6940
2019
Q1
$23K Sell
2,822
-1,184
-30% -$12.2K ﹤0.01% 6894
2018
Q4
$64K Buy
4,006
+109
+3% +$2.4K ﹤0.01% 6033
2018
Q3
$128K Buy
3,897
+1,676
+75% +$43.1K ﹤0.01% 5677
2018
Q2
$50K Buy
2,221
+2,037
+1,107% +$48.3K ﹤0.01% 6294
2018
Q1
$5K Sell
184
-84
-31% -$2.46K ﹤0.01% 7229
2017
Q4
$7K Buy
268
+1
+0.4% +$31 ﹤0.01% 7164
2017
Q3
$10K Buy
267
+176
+193% +$5.44K ﹤0.01% 6706
2017
Q2
$2K Buy
+91
New +$716 ﹤0.01% 7074
2016
Q2
Sell
-29
Closed 7627
2016
Q1
$0 Sell
29
-6
-17% -$59 ﹤0.01% 7937
2015
Q4
$0 Buy
+35
New +$416 ﹤0.01% 8025
2015
Q3
Sell
-36
Closed -$1K 7936
2015
Q2
$1K Buy
+36
New +$648 ﹤0.01% 7392
2015
Q1
Sell
-100
Closed -$1K 7561
2014
Q4
$1K Buy
100
+67
+203% +$613 ﹤0.01% 7025
2014
Q3
$0 Sell
33
-123
-79% -$1.56K ﹤0.01% 7417
2014
Q2
$3K Sell
156
-3,781
-96% -$49.2K ﹤0.01% 6673
2014
Q1
$59K Buy
3,937
+1,907
+94% +$34.3K ﹤0.01% 5389
2013
Q4
$37K Buy
2,030
+48
+2% +$961 ﹤0.01% 5870
2013
Q3
$41K Sell
1,982
-312
-14% -$7.14K ﹤0.01% 5427
2013
Q2
$58K Buy
+2,294
New +$98.1K ﹤0.01% 5280

Citigroup's AVEO Position: Q1 2023 in Review

Citigroup sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 775 shares — an estimated $11.6K sold.

Citigroup first reported a position in AVEO in Q2 2013 and held it in 31 quarters. The position peaked at $128K in Q3 2018. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.

  • Citigroup reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Citigroup sold 775 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $11.6K.
  • Citigroup first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2013 and held it in 31 quarters.
  • Citigroup's AVEO Pharmaceuticals, Inc. position peaked at $128K in Q3 2018.
  • 0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.

Based on Citigroup's 13F filing for Q1 2023, filed 11 May 2023.